Life Science Reagents

Protein Metrics provides vendor‑neutral mass spectrometry software for biotherapeutic protein and oligo analysis, spanning research through industrial production. Its Byonic, Byos and Byosphere products support protein identification, characterization, automated workflows and enterprise‑level reporting from heterogeneous analytical platforms. The company is headquartered in Boston, Massachusetts, and focuses on enabling accurate, reproducible, and scalable protein analytics for biopharma and research labs.

Miltenyi Biotec is a global biotechnology company headquartered in Bergisch Gladbach, Germany, specializing in magnetic cell separation (MACS), life science reagents, and instruments for cell and gene therapy workflows. Through its Miltenyi Bioindustry division, it also provides CDMO services for cell‑based therapies and lentiviral vectors from preclinical to commercial scale.

Lunaphore, a Bio-Techne Spatial brand based in Switzerland, provides automated spatial biology platforms for high‑plex IF/IHC and multiomics on tissue. Its COMET™ instrument, SPYRE™ panels, HORIZON™ software and Access Lab services help pharma and biotech teams rapidly develop and scale spatial biomarker programs across translational and clinical research.

NanoTemper Technologies is a founder-owned biophysical characterization company providing instruments, consumables, and reagents for binding affinity and protein stability analysis across discovery and development. With systems like Prometheus Panta, Monolith, Dianthus and Andromeda, NanoTemper helps pharma and biotech teams obtain high-precision, reproducible in-solution data for biologics, targeted protein degradation, and complex membrane proteins, supported by global locations in Munich and South San Fr

NanoTemper Technologies is a privately held biophysical instrumentation company that provides binding affinity, protein stability, and high‑throughput screening solutions for biologics and complex targets. Headquartered in Munich with global offices, it offers instruments, consumables, and reagents designed for high precision, reproducibility, and seamless workflow integration from discovery to regulatory filing.

NEOsphere Biotechnologies GmbH is a Germany-based proteomics company specializing in targeted protein degradation and induced proximity drug discovery. It offers deep proteomic screening, global ubiquitinomics, high-throughput interactomics, activity-based protein profiling, and AI-powered data analysis to support hit discovery, lead optimization, and mechanistic validation of degrader and proximity-inducing molecules.

Nicoya Lifesciences Inc. is a private Canadian company providing advanced label-free biophysical tools for protein binding, structure, stability, and kinetics. Its portfolio includes digital SPR platforms (Alto, Revo, OpenSPR), the FastHDX millisecond HDX‑MS protein dynamics platform, and complementary CD, DSF, and kinetics systems, serving pharma, biotech, and academic R&D teams worldwide.

Nona Biosciences is a private biotechnology company in Cambridge, Massachusetts, offering fully human antibody discovery and integrated biotherapeutic development services. Its portfolio includes Harbour Mice® HCAb/H2L2, Hu-mAtrIx™ AI discovery, NonaCarFx™, and Modalities-on-Demand® for ADCs, bispecifics, CAR-based cell therapy, mRNA, siRNA, and BBB delivery.

Glen Research supplies high‑performance reagents and supports for DNA and RNA oligonucleotide synthesis, modification, labeling, and purification, with a strong focus on compatibility with commercial synthesizers. Its portfolio includes GalNAc delivery supports, fluorophores, modifiers, universal supports, ancillary reagents, and DMT‑based purification consumables tailored for in‑house oligo synthesis in pharma, biotech, and genomics labs.

Olink, part of Thermo Fisher Scientific, provides high-throughput, affinity-based proteomics platforms and assays based on Proximity Extension Assay (PEA) technology for protein biomarker analysis from small sample volumes. Its Explore series, targeted panels and Olink Insight bioinformatics app support discovery-to-translation biomarker and proteogenomics research across major disease areas, and the company is headquartered in Uppsala, Sweden.

Olink, part of Thermo Fisher Scientific, delivers next-generation proteomics platforms based on proprietary PEA technology and NGS readouts, enabling high-throughput, highly specific protein biomarker analysis from small sample volumes. Its discovery-scale and targeted panels, together with the Olink Insight bioinformatics app, support pharma, biobank, and academic teams across major disease areas from biomarker discovery to precision medicine.

Cyprumed GmbH is an Innsbruck-based drug delivery technology company specializing in proprietary oral peptide and biologic delivery platforms, including intestinal, gastric and BCS Class IV tablet technologies. It collaborates with major pharma companies such as MSD, Bayer, Boehringer Ingelheim and Ferring to transform injectable peptides and other complex molecules into scalable, orally bioavailable drug products.

PhoreMost is a Cambridge, UK-based private biotech company focused on oncology, developing small molecule drugs and bifunctional degraders for cancers of high unmet clinical need. Its lead program PMC-001 targets primary and metastatic brain cancers, alongside additional HPV+ and degrader-based oncology assets, supported by proprietary chemistry against novel E3 ligases and active partnering opportunities.

Phylloceuticals is a privately held pharmaceutical manufacturing and technology company that produces therapeutic proteins and biosimilars using plant-based systems. It focuses on cleaner, faster, more affordable medicine with a strong social-impact and national security mission, offering scalable plant-made biologics and biosimilar drug product to commercialization entities and healthcare systems.

Alamar Biosciences offers a fully automated Precision Proteomics Platform that combines NULISA technology with the ARGO instrument for ultra-high sensitivity, multiplex protein biomarker analysis from very small sample volumes. With ready-to-use inflammation and CNS panels, custom assay tools, and sample analysis services, it supports biomarker discovery and translational research in pharma and biotech. The company is headquartered in Fremont, California.

ProBioGen AG is a Berlin-based, fully integrated CDMO providing end-to-end development and GMP manufacturing services for biopharmaceuticals, viral vectors and vaccines. It offers cell line and process development, cell banking, analytics and GMP production for proteins, antibodies and viral vectors, supported by proprietary platforms such as GlymaxX, CHO.RiGHT, DirectedLuck, MVA-CR19, Lenti.RiGHT and AGE1.

ProImmune is a UK-based biotechnology company specializing in immunology reagents and services that support basic, preclinical, and clinical research. Its portfolio includes Ankyrons next-generation binding reagents, MHC tetramers and pentamers, peptide pools, custom peptide synthesis, and comprehensive immunogenicity and immunotoxicology assay services for biotherapeutic and vaccine development.

Promega Corporation is a privately owned biotechnology company headquartered in Madison, Wisconsin, supplying over 4,000 products for genomics, protein analysis, cellular analysis, drug discovery and human identification. It provides assays, reagents and instruments along with technical support to enable small molecule drug discovery, cell and gene therapy workflows, clinical diagnostics and forensic DNA analysis for customers worldwide.

RedShiftBio is a privately held biotech instrumentation company headquartered in Boxborough, Massachusetts, providing Aurora TX MMS platforms for biophysical characterization of proteins, peptides and RNA, and HaLCon analyzers for real‑time, HPLC‑level protein titer measurement in bioprocessing. Its solutions support biopharmaceutical research, development and manufacturing of protein therapeutic drugs and RNA‑based modalities.

Protein Dynamic Solutions provides the ProteinMentor platform for high-throughput critical quality attribute analysis, developability, comparability, and release testing of therapeutic proteins and biosimilars. Using quantum cascade laser–based hyperspectral imaging, it characterizes aggregation, stability, charge variants, identity, and formulation impact for both drug substance and drug product, with 21 CFR Part 11 compliant data handling to support regulatory-focused biopharmaceutical development and man

ProteomEdge is a Swedish proteomics company providing multiplex panels of isotope‑labelled protein standards for absolute protein quantification in plasma using mass spectrometry. Its qRePS™-based portfolio, including ApoEdge™, DiscoveryEdge™175/600, ComplemEdge and LiverEdge, targets clinically relevant biomarkers across apolipoproteins, complement, inflammation and liver disease. The products support scalable, high-precision plasma proteomics for research and translational applications.

Biognosys (Proteomic Solutions) is a global leader in next-generation, mass spectrometry–based proteomics for pharma and biotech R&D and clinical development. It offers contract research services, advanced proteomics software, and peptide kits/reagents that enable deep, unbiased protein quantification across tissues and biofluids, supporting biomarker discovery, target validation, and precision medicine.

ProteoNic BioSciences provides the 2G UNic® platform to increase gene expression and titers in CHO, HEK and yeast systems. Its vector and transposon technologies deliver multi‑fold productivity gains, faster high‑producing cell line development and stable long‑term expression for biologics, biosimilars and advanced therapies. The platform is used by biopharma and CDMOs globally as an easy, drop‑in upgrade to existing workflows.

Protheragen Inc. is a New York–headquartered biopharmaceutical project incubator and investment platform focused on early-stage, first‑in‑class therapeutics. It offers project incubation, equity investment, and cross‑border BD consulting, managing a broad pipeline of antibody, protein, small molecule, cell and gene therapy programs across oncology, metabolic, inflammatory, and infectious disease indications. The company connects innovative assets with global partners to support licensing, co‑development, an